Glial scar (astrocytic scar)

The **glial scar** is a multicellular, non-molecular structure that forms after injury to the central nervous system (CNS), particularly in the spinal cord and brain[4][5][1][2]. The main cellular component of the glial scar is the reactive astrocyte, which undergoes hypertrophy, proliferation, and increased expression of glial fibrillary acidic protein (GFAP)[4][5]. These astrocytes and associated extracellular matrix components (including chondroitin sulfate proteoglycans, tenascin, laminin, and fibronectin) create a dense physical and chemical barrier that inhibits axonal regrowth and contributes to regeneration failure after CNS injury[2][4][6]. Glial scar formation is a key adaptive process to limit secondary damage and restore protective barrier functions, but it presents a dual role: while crucial for neuroprotection and inflammation containment, its dense structure actively inhibits neuronal and axonal regeneration in the chronic phase[3][4][5]. The molecular inducers of glial scar formation include cytokines such as transforming growth factor-beta (TGF-β), interleukins, interferon-γ, and fibroblast growth factor 2 (FGF2)[4]. Modulating the properties or formation of the glial scar is a major therapeutic strategy to improve CNS regeneration, but the glial scar itself is not a single molecular drug target and cannot be addressed as a typical receptor, enzyme, or transporter[3][5][6]. Because "Physical support for axonal growth/inhibition of glial scar formation" describes a therapeutic strategy or process and not a discrete molecular entity, receptor, protein, or gene, it is **not a valid target name** under established nomenclatures. Specific molecules or pathways within the glial scar can be considered valid targets (e.g., chondroitin sulfate proteoglycans, STAT3, GFAP), but "glial scar formation" as a whole is not a canonical molecular target[3][4][5][6].

Other names

Glial astrocytic scarastroglial scarglial fibrous scarastrocytic scar